Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Univariate analysis for overall survival time.

From: Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2 homodimers in a clinic-based cohort of patients with metastatic breast cancer

Variable Category Hazard ratio 95% C.I. P-value
Treatment group trastuzumab/trastzumab+chemo 1.24 0.43 3.56 0.693
ER +/- 0.81 0.28 2.33 0.694
PR +/- 0.45 0.14 1.49 0.190
Hormone receptor +/- 0.53 0.19 1.54 0.244
Tumor stage Recurrence/advanced 3.30 0.45 24.4 0.242
No. of metastatic sites 1/2/3/4 0.54 0.37 0.79 0.002
Liver mets No/Yes 0.74 0.34 1.59 0.435
Lung mets No/Yes 0.83 0.40 1.72 0.615
Bone mets No/Yes 0.42 0.20 0.88 0.021
Lymph node mets No/Yes 1.02 0.49 2.14 0.959
Brain mets No/Yes 0.18 0.07 0.46 <.0001